Jeffrey H. Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeffrey H. Lin has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Poltorak
Department of Immunology, Tufts University School of Medicine, Boston, MA 02111, USA
10 shared publications - Colm Morrissey
Department of Urology, University of Washington, Seattle, Washington
10 shared publications - Daniel Fein
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
10 shared publications - Fei Song
Division of Hematology-Oncology, Tufts Medical Center, Boston, Massachusetts
10 shared publications - Kun Hu
Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, Massachusetts
10 shared publications - Ming Zhou
Icahn School of Medicine at Mount Sinai
10 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
BsAb𝑎5β1/𝑎v inhibits nuclear localization of integrin-regulated markers of mechanotransduction in PC-3 cells
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
BsAb𝑎5β1/𝑎v inhibits nuclear localization of integrin-regulated markers of mechanotransduction in PC-3 cells
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
Lack of efficacy of BsAb𝑎5β1/𝑎v in the NSG background
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
Lack of efficacy of BsAb𝑎5β1/𝑎v in the NSG background
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
BsAb𝑎5β1/𝑎v controls clonogenic survival of DU-145 PTENmt cells
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
BsAb𝑎5β1/𝑎v controls clonogenic survival of DU-145 PTENmt cells
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
Mechanistic overview: Abrogation of Integrin/YAP mechanosignaling by the BsAbα5β1/αv disables Myc-regulated immunosuppression
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
Mechanistic overview: Abrogation of Integrin/YAP mechanosignaling by the BsAbα5β1/αv disables Myc-regulated immunosuppression
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
FAK and Src/Abl inhibition fails to block nuclear localization of YAP, β-catenin or FAK in DU-145 cells
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
FAK and Src/Abl inhibition fails to block nuclear localization of YAP, β-catenin or FAK in DU-145 cells
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
BsAb𝑎5β1/𝑎v suppresses Myc/E2F signaling and induces type I and type II interferon response pathways in basal-type cancer cells
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
BsAb𝑎5β1/𝑎v suppresses Myc/E2F signaling and induces type I and type II interferon response pathways in basal-type cancer cells
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Data from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
Integrin α5β1 and αv cross-talk in chemotaxis, and clonogenic survival of prostate cancer cells is abrogated by a bispecific α5β1/αv antibody (BsAbα5β1/αv), which uniquely induces internalization and lysosomal degradation of target integrins. We hypothesized that the BsAbα5β1/αv inactivates pathologic mechanosignaling pathways that correlate with integrin expression from patient samples. Mechanistic studies indicate that the BsAbα5β1/αv uniquely reverses Yes-associated protein, β-catenin, and focal adhesion kinase nuclear localization compared with monospecific integrin α5β1 and αv antibody controls in basal-type androgen receptor–negative prostate cancer cells. Dual integrin αv and α5 knockdown alone phenocopied the BsAbα5β1/αv effect. Following BsAbα5β1/αv treatment, Assay for Transposase-Accessible Chromatin using sequencing studies indicated the chromatin accessibility to TEAD and AP-1 family members was markedly reduced. In vitro and in vivo RNA sequencing indicated downregulation of Myc/E2F, TGF-β, and epithelial–mesenchymal transition and upregulation of type I and II IFN transcriptomic pathways. The BsAbα5β1/αv induced CXCL10 and CCL5 cytokine secretion, immune-infiltration of tumors, and NK cell–mediated elimination of the basal-type prostate cancer xenografts in nude mice. αv integrin was highly expressed and principally correlated with the Myc signaling pathway in rapid autopsy tissue microarrays, consistent with correlative data from the SU2C metastatic castration-resistant prostate cancer and Deutsches Krebsforschungszentrum early-onset prostate cancer cohorts. These studies connect integrin signaling with the central biology of basal-type and castration-resistant prostate cancers and define a novel therapeutic strategy that controls critical immunosuppressive pathways.Implications:Dual integrin α5β1/αv targeting with a bispecific antibody represents a novel therapeutic strategy that reprograms the epigenetic and transcriptomic signatures of basal-type prostate cancer with induction of immunologic tumor control.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
Integrin α5β1 and αv cross-talk in chemotaxis, and clonogenic survival of prostate cancer cells is abrogated by a bispecific α5β1/αv antibody (BsAbα5β1/αv), which uniquely induces internalization and lysosomal degradation of target integrins. We hypothesized that the BsAbα5β1/αv inactivates pathologic mechanosignaling pathways that correlate with integrin expression from patient samples. Mechanistic studies indicate that the BsAbα5β1/αv uniquely reverses Yes-associated protein, β-catenin, and focal adhesion kinase nuclear localization compared with monospecific integrin α5β1 and αv antibody controls in basal-type androgen receptor–negative prostate cancer cells. Dual integrin αv and α5 knockdown alone phenocopied the BsAbα5β1/αv effect. Following BsAbα5β1/αv treatment, Assay for Transposase-Accessible Chromatin using sequencing studies indicated the chromatin accessibility to TEAD and AP-1 family members was markedly reduced. In vitro and in vivo RNA sequencing indicated downregulation of Myc/E2F, TGF-β, and epithelial–mesenchymal transition and upregulation of type I and II IFN transcriptomic pathways. The BsAbα5β1/αv induced CXCL10 and CCL5 cytokine secretion, immune-infiltration of tumors, and NK cell–mediated elimination of the basal-type prostate cancer xenografts in nude mice. αv integrin was highly expressed and principally correlated with the Myc signaling pathway in rapid autopsy tissue microarrays, consistent with correlative data from the SU2C metastatic castration-resistant prostate cancer and Deutsches Krebsforschungszentrum early-onset prostate cancer cohorts. These studies connect integrin signaling with the central biology of basal-type and castration-resistant prostate cancers and define a novel therapeutic strategy that controls critical immunosuppressive pathways.Implications:Dual integrin α5β1/αv targeting with a bispecific antibody represents a novel therapeutic strategy that reprograms the epigenetic and transcriptomic signatures of basal-type prostate cancer with induction of immunologic tumor control.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
BsAbα5β1/αv activates NF-κB and IRF7 in DU-145 cells
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
BsAbα5β1/αv activates NF-κB and IRF7 in DU-145 cells
- 23 June 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 23 (10) , 873-888
A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
Integrin α5β1 and αv cross-talk in chemotaxis, and clonogenic survival of prostate cancer cells is abrogated by a bispecific α5β1/αv antibody (BsAbα5β1/αv), which uniquely induces internalization and lysosomal degradation of target integrins. We hypothesized that the BsAbα5β1/αv inactivates pathologic mechanosignaling pathways that correlate with integrin expression from patient samples. Mechanistic studies indicate that the BsAbα5β1/αv uniquely reverses Yes-associated protein, β-catenin, and focal adhesion kinase nuclear localization compared with monospecific integrin α5β1 and αv antibody controls in basal-type androgen receptor–negative prostate cancer cells. Dual integrin αv and α5 knockdown alone phenocopied the BsAbα5β1/αv effect. Following BsAbα5β1/αv treatment, Assay for Transposase-Accessible Chromatin using sequencing studies indicated the chromatin accessibility to TEAD and AP-1 family members was markedly reduced. In vitro and in vivo RNA sequencing indicated downregulation of Myc/E2F, TGF-β, and epithelial–mesenchymal transition and upregulation of type I and II IFN transcriptomic pathways. The BsAbα5β1/αv induced CXCL10 and CCL5 cytokine secretion, immune-infiltration of tumors, and NK cell–mediated elimination of the basal-type prostate cancer xenografts in nude mice. αv integrin was highly expressed and principally correlated with the Myc signaling pathway in rapid autopsy tissue microarrays, consistent with correlative data from the SU2C metastatic castration-resistant prostate cancer and Deutsches Krebsforschungszentrum early-onset prostate cancer cohorts. These studies connect integrin signaling with the central biology of basal-type and castration-resistant prostate cancers and define a novel therapeutic strategy that controls critical immunosuppressive pathways. Implications: Dual integrin α5β1/αv targeting with a bispecific antibody represents a novel therapeutic strategy that reprograms the epigenetic and transcriptomic signatures of basal-type prostate cancer with induction of immunologic tumor control.
- 23 June 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 23 (10) , 873-888
A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
Integrin α5β1 and αv cross-talk in chemotaxis, and clonogenic survival of prostate cancer cells is abrogated by a bispecific α5β1/αv antibody (BsAbα5β1/αv), which uniquely induces internalization and lysosomal degradation of target integrins. We hypothesized that the BsAbα5β1/αv inactivates pathologic mechanosignaling pathways that correlate with integrin expression from patient samples. Mechanistic studies indicate that the BsAbα5β1/αv uniquely reverses Yes-associated protein, β-catenin, and focal adhesion kinase nuclear localization compared with monospecific integrin α5β1 and αv antibody controls in basal-type androgen receptor–negative prostate cancer cells. Dual integrin αv and α5 knockdown alone phenocopied the BsAbα5β1/αv effect. Following BsAbα5β1/αv treatment, Assay for Transposase-Accessible Chromatin using sequencing studies indicated the chromatin accessibility to TEAD and AP-1 family members was markedly reduced. In vitro and in vivo RNA sequencing indicated downregulation of Myc/E2F, TGF-β, and epithelial–mesenchymal transition and upregulation of type I and II IFN transcriptomic pathways. The BsAbα5β1/αv induced CXCL10 and CCL5 cytokine secretion, immune-infiltration of tumors, and NK cell–mediated elimination of the basal-type prostate cancer xenografts in nude mice. αv integrin was highly expressed and principally correlated with the Myc signaling pathway in rapid autopsy tissue microarrays, consistent with correlative data from the SU2C metastatic castration-resistant prostate cancer and Deutsches Krebsforschungszentrum early-onset prostate cancer cohorts. These studies connect integrin signaling with the central biology of basal-type and castration-resistant prostate cancers and define a novel therapeutic strategy that controls critical immunosuppressive pathways. Implications: Dual integrin α5β1/αv targeting with a bispecific antibody represents a novel therapeutic strategy that reprograms the epigenetic and transcriptomic signatures of basal-type prostate cancer with induction of immunologic tumor control.